Chemical Biology & Drug Design
© John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Edited By: David Selwood
Impact Factor: 2.282
ISI Journal Citation Reports © Ranking: 2011: 30/59 (Chemistry Medicinal); 182/290 (Biochemistry & Molecular Biology)
Online ISSN: 1747-0285
Recently Published Issues
Current Issue:June 2013
Volume 81, Issue 6
Volume 81, Issue 5
Volume 81, Issue 4
Volume 81, Issue 3
Volume 81, Issue 2
Publish with CB & DD
Reasons to publish with CB & DD
• Rapid review and publishing: 30 days on average from submission to first decision. We discourage reviewers from requesting “additional experiments”.
• Simple initial submission process, can load a single PDF.
• Fully indexed in PubMed/MEDLINE, Chemical Abstracts etc.
• International editors from different specialities to oversee the review process.
• No page charges for first seven (typeset) pages, no charge for colour figures.
• Open Access publication option.
• Compliant to NIH, RCUK and other major funding bodies policies.
Recently Published Articles
- Rationally Designed Sulfamides As Glutamate Carboxypeptidase II (GCPII) Inhibitors
Cindy J. Choy, Melody D. Fulton, Austen L. Davis, Mark Hopkins, Joseph K. Choi, Marc O. Anderson and Clifford E. Berkman
Accepted manuscript online: 17 JUN 2013 06:26AM EST | DOI: 10.1111/cbdd.12174

This current study explores a new class of GCP II inhibitors, glutamyl sulfamides, which possess a neutral tetrahedral zinc-binding motif. A small library containing 6 sulfamides was prepared and evaluated for inhibitory potency against purified GCPII. While most inhibitors have potencies in the micromolar range, one showed promising sub-micromolar potency, with the optimal inhibitor in this series being aspartyl-glutamyl sulfamide
- Evaluation of the efficiency of synthesized efflux pump inhibitors on Salmonella enterica ser. Typhimurium cells
Simona Sutkuvienė, Valeryia Mikalayeva, Silvia Pavan, Federico Berti and Rimantas Daugelavičius
Accepted manuscript online: 13 JUN 2013 09:46AM EST | DOI: 10.1111/cbdd.12173

This study was focused on the evaluation of efficiency of synthesized resistance-nodulation-division (RND) family efflux pump inhibitors. Efficiency of the synthesized compounds was investigated on Salmonella enterica ser. Typhimurium cells using electrochemical and spectrofluorimetric methods. The results obtained showed that the registered efficiency of inhibitors depends on the permeability of cell outer membrane and the method of assay used.
- Evaluating the predictivity of virtual screening for Abl kinase inhibitors to hinder drug resistance
Osman A B S M Gani, Dilip Narayanan and Richard A. Engh
Accepted manuscript online: 8 JUN 2013 07:12AM EST | DOI: 10.1111/cbdd.12170

Virtual screenings were performed on ABL1 kinase to study inhibitors for wild type T315 mutant form. In addition, chemoinformatic methods were also applied on kinase inhibitors. We show that VS and ligand-based studies are complementary in understanding the features that should be considered during in silico studies.
- TAK1 Inhibition in theDFG-Out Conformation
Iain Kilty, Martin P. Green, Andrew S. Bell, David G. Brown, Peter G. Dodd, Christopher Hewson, Samantha J. Hughes, Christopher Phillips, Thomas Ryckmans, Robert T. Smith, Willem P. van Hoorn, Philip Cohen and Lyn H. Jones
Accepted manuscript online: 7 JUN 2013 11:26AM EST | DOI: 10.1111/cbdd.12169

The first example of an inhibitor of the kinase TAK1 that binds in the DFG-out conformation is disclosed. These preliminary studies used kinase-targeted screening and structure-based drug design to create a molecule with dual pharmacological inhibition of p38 and TAK1 that demonstrated significant activity in a cell-based, anti-inflammatory assay.
- Preptin Analogues: Chemical Synthesis, Secondary Structure and Biological Studies
Christina M. Buchanan, Zhenzhen Peng, Aiko Cefre and Vijayalekshmi Sarojini
Accepted manuscript online: 7 JUN 2013 11:26AM EST | DOI: 10.1111/cbdd.12168

1747-0285/asset/olbannerleft.gif?v=1&s=06fc3781ca54dcd57186e8e823bbd5b5dd027f19)
1747-0285/asset/olbannerright.gif?v=1&s=e142e5373cf24ea16bd18b4ae82dc201f9d35538)
